title: Docosahexaenoic Acid Induces Apoptosis in Primary Chronic Lymphocytic Leukemia Cells.
abstract: Chronic lymphocytic leukemia is an indolent disorder with an increased infectious risk remaining one of the main causes of death. Development of therapies with higher safety profile is thus a challenging issue. Docosahexaenoic acid (DHA, 22:6) is an omega-3 fatty acid, a natural compound of normal cells, and has been shown to display antitumor potency in cancer. We evaluated the potential in vitro effect of DHA in primary CLL cells. DHA induces high level of in vitro apoptosis compared to oleic acid in a dose-dependent and time-dependent manner. Estimation of IC50 was only of 4.813 µM, which appears lower than those reported in solid cancers. DHA is highly active on CLL cells in vitro. This observation provides a rationale for further studies aiming to understand its mechanisms of action and its potent in vivo activity.
authors.affiliation: Service de Thérapie Cellulaire et d'Hématologie Clinique Adulte, Hôpital Estaing, CHU de Clermont-Ferrand; Cancer Resistance Exploring and Targeting EA 7283, Université d'Auvergne 1, Clermont-Ferrand.
authors.forename: Romain
authors.initials: R
authors.lastname: Guièze
authors.affiliation: Service d'Hématologie et de thérapie cellulaire, Centre Hospitalier Universitaire, CHU de Tours; Université François Rabelais, Tours.
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Gyan
authors.affiliation: Service de Thérapie Cellulaire et d'Hématologie Clinique Adulte, Hôpital Estaing, CHU de Clermont-Ferrand; Cancer Resistance Exploring and Targeting EA 7283, Université d'Auvergne 1, Clermont-Ferrand.
authors.forename: Olivier
authors.initials: O
authors.lastname: Tournilhac
authors.affiliation: Université François Rabelais , Tours.
authors.forename: Christelle
authors.initials: C
authors.lastname: Halty
authors.affiliation: Cancer Resistance Exploring and Targeting EA 7283, Université d'Auvergne 1, Clermont-Ferrand; Laboratoire d'Hématologie, Hôpital Estaing, CHU de Clermont-Ferrand.
authors.forename: Richard
authors.initials: R
authors.lastname: Veyrat-Masson
authors.affiliation: Laboratoire d'Hématologie, Hôpital Estaing , CHU de Clermont-Ferrand.
authors.forename: Saïda
authors.initials: S
authors.lastname: Akil
authors.affiliation: Cancer Resistance Exploring and Targeting EA 7283, Université d'Auvergne 1, Clermont-Ferrand; Laboratoire d'Hématologie, Hôpital Estaing, CHU de Clermont-Ferrand.
authors.forename: Marc
authors.initials: M
authors.lastname: Berger
authors.affiliation: Université François Rabelais , Tours.
authors.forename: Olivier
authors.initials: O
authors.lastname: Hérault
authors.forename: Mary
authors.initials: M
authors.lastname: Callanan
authors.affiliation: Service de Thérapie Cellulaire et d'Hématologie Clinique Adulte, Hôpital Estaing, CHU de Clermont-Ferrand; Cancer Resistance Exploring and Targeting EA 7283, Université d'Auvergne 1, Clermont-Ferrand.
authors.forename: Jacques-Olivier
authors.initials: JO
authors.lastname: Bay
keywords: Chronic lymphocytic leukemia; docosahexaenoic acid